|
Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, single-arm, open-label study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Hengrui Pharmaceutical ; Innovent Biologics; Lilly; Merck; MSD; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - BetaPharma (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - BeiGene; Roche |
Consulting or Advisory Role - Hansoh Pharma |
Research Funding - Hansoh Pharma (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - BetaPharma (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson; Pfizer |
Patents, Royalties, Other Intellectual Property - BetaPharma (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |